OBJECTIVES:
The economic crisis has led Greece to adopt measures towards reducing public pharmaceutical expenditure. One of the most important key sectors addressed was that of the market share of generics. The aim of the study was to evaluate stakeholder's perceptions of the recently introduced or planned pharmaceutical policy reforms regarding generics policy in Greece. METHODS: A qualitative study, using the method of semi-structured interviews was conducted. We identified 24 decision makers and opinion leaders from public and private organizations, after developing an influence map. In total 17 interviews were conducted, using an open-ended questions guide. The interviews were tape recorded, transcribed and content analyzed. RESULTS: The majority of stakeholders perceived the prices of generics as "high" and "non-competitive" and their pricing system as problematic, also highlighting the lack of incentives for increased use of generics that results in low penetration in the market. An important issue strongly emphasized was the introduction of stricter audit and quality control mechanisms. Regarding INN prescribing, stakeholders appeared to be skeptical for both its effectiveness and its viability, as concerns focusing on the maturity of the system, on the culture and education of the physicians and on the lack of monitoring mechanisms, cannot guarantee its effective implementation. CONCLUSIONS: There is general agreement that a generics policy in Greece should aim at having low prices and higher generic penetration in the market, by introducing incentives for all stakeholders as well as ensuring the quality and safety of generics. The introduction of INN was not clearly deemed as a measure that can assist to achieve the goal of containing pharmaceutical expenditure. The pricing system of generics has now been reformed, leading to lower prices. Further policy measures are needed in the framework of a comprehensive generics policy in order to increase generics consumption. OBJECTIVES: Identify differences of biosimilar uptakes across the EU big five: France, Italy, Germany, UK, Spain, and USA. METHODS: We identified policies and biosimilars market shares in volume and value in EU big five: France, Italy, Germany, UK, Spain and USA. We browsed websites of EU and national (when applicable) drug agencies, ministries of health, HTA bodies, payers, manufacturer unions etc. We completed our research with literature search and grey reports, as well as Datamonitor reports, IMS data and proprietary pharmavitae database. RESULTS: Contrary to FDA, EMA has a well defined regulatory path for biosimilars. However, when the US Patient Protection and Affordable Care Act 2010 enters into force in 2014, the biosimilars market will be boosted. Today 80% of this market is in EU. While uptakes in Spain and UK have started to increase, Germany and France account currently for half of the biosimilars market by value in EU with a 36% and 19% share respectively. In UK, biosimilars have had low penetration, and in Italy the market is far behind other countries. Other countries with apparently high sales of biosimilars like Greece are source countries for parallel market. Obviously there is no overlap between the generics market size and the biosimilars one. The slow uptake versus generics can be explained by the low discount of biosimilar price versus branded products and the uncertainty about the clinical effect. CONCLUSIONS: The lack of regulatory path in USA makes difficult the launch of biosimilars. However, EU is the experimental field where companies develop their ability to capture this market. Small molecule generics continue representing the main source of cost savings in Europe. Biosimilars represent a huge opportunity for cost saving in the future especially in the USA where the biologic market is leader. 
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PHP94 DETERMINANTS OF DRUG THERAPY PROBLEMS AMONG MEDICAID PATIENTS RECEIVING A TELEPHONIC MEDICATION THERAPY MANAGEMENT PROGRAM
OBJECTIVES:
To examine predictors of drug therapy problems (DTP) among patients who received a telephonic medication therapy management (MTM) program. METHODS: Retrospective data was collected from 712 Medicaid patients who received an initial medication therapy review (MTR) as part of a statewide telephonic MTM program during an 18-month period. Data was extracted from two administrative claims files for health care utilization and prescription dispensing information and one medical record file for MTM program information. For analyses, the main outcome variable was the number of pharmacist-identified DTPs during the initial MTR. Univariate and multivariate models examined the variables of age, sex, co-morbid conditions, number of inpatient, outpatient, and emergency department (ED) visits, number of total, chronic, and narrow therapeutic index drugs, total medication doses per day, and the number of prescribers and dispensing pharmacies for their relationship with the main outcome. For all medication and service utilization variables, only data from the three months prior to the MTR were included. RESULTS: At least one DTP was identified in 61.1% of patients (per patient meanϭ 22 ϩ/Ϫ 25.) Univariate analyses found that female sex, diagnosis of hyperlipidemia, number of ED visits, number of total and chronic medications, total medication doses per day, and the number of pharmacies where patients had prescriptions filled were significantly (p Ͻ 0.05) associated with having more DTPs. In multivariate analyses, female sex, diagnosis of hyperlipidemia, number of ED visits, and number of total and chronic medications remained as significant predictors (pϽ0.05) of DTPs. In sensitivity analyses for 10, 20, 30, and 40 or more DTPs per patient, these variables remained significant predictors in the models except for number of chronic medications. CONCLUSIONS: Providers and policymakers planning the implementation of MTM services, particularly for Medicaid patients, may benefit from considering these findings in defining targeted populations for service delivery. 
PHP95 EFFICIENCY OF GREEK HOSPITALS: BEST PRACTICES OF THREE TOP-PERFORMING HOSPITALS
OBJECTIVES:
The objective of this paper was to examine the performance of 90 public general hospitals of the Greek National Health System (GNHS) in 2010, rank hospitals according to their efficiency and identify potentials for input reductions. Additionally, the aim of the study was to identify best practices regarding procurement policies for pharmaceuticals and other medical goods used by the most efficient hospitals. METHODS: Data Envelopment Analysis (DEA) was used for the estimation of efficiency scores. The number of beds, doctors, management and nursing personnel and total hospital expenditures were used as inputs and number of patient admissions, patient days, outpatient visits and surgical interventions as outputs. In order to identify best practices regarding the efficient performance of the leading hospitals, a panel of academic experts and executives of the three top performing hospitals, was used. RESULTS: The results show that only 31% of Greek hospitals are efficient, with a mean efficiency score of 85.5%. Among hospitals with the highest efficiency scores (100%) were two University hospitals and one privatenon profit hospital. All three hospitals managed on average, an 11.6% decrease in pharmaceutical expenditure and 20.1% in the procurement of orthopaedics-prosthetics and other medical goods compared to the previous year. At the same time, the number of admissions increased on average by 8.1% and the number of surgical interventions also increased in to hospitals by more than 2%. Regarding the best practices used, the experts agreed that among the most effective procurement policies are tendering and renegotiation with a number of suppliers. Additionally, they all agreed that the introduction of e-procurement decreased pharmaceutical and other medical goods consumption. CONCLUSIONS: If the GNHS was to eliminate inefficiency it could save up to 208.5 million euro or 10.3 % of the total budget allocated to public hospitals in 2010. 
PHP96 EVIDENCE BASED STRUCTURAL REFORM IN THE PROVISION OF HOSPITAL CARE: THE CASE STUDY OF MERGING TWO INSTITUTIONS IN HUNGARY
OBJECTIVES:
In difficult economic periods policymakers implement cost-contaiment measures in the specialty care. Therefore hospital managers have to improve the technical efficiency of operation. In Hungary merger of hospitals were initiated to take advantage of economies of scale. Our objective was to assess whether the merger of the Clinical Center of University of Pecs and the Hospital of Baranya County in 2010 improved the sustainability and technical efficiency of these institutions. METHODS: Our analysis was based on data from the controlling system of these institutions. We compared revenues, costs, number of cases and performance data before (2009) and after the merger (2011). RESULTS: After the merger the National Health Insurance Fund Administration (NHIFA) cut the performance volume limit (PVL) of the institution by 11,7%. This resulted in a reduction of patient volumes and revenues. The number of cases decreased differentially: it fell by 9,2% on those departments that were previously operated parallel by both institutions, and only by 2,7% on those department that were earlier only operated by the Clinical Center. The total bed utilization rate also declined by 6,2%. The management of the Clinical Center could reduce the operational costs by 958 million HUF by decreasing the number of staff and renegotiating supply contracts. However due to the decreasing PVL the cost/DRG increased from 136'600 to 149'600 HUF/DRG. CONCLUSIONS: The management of the hospitals applied ceteris paribus assumptions when predicting the outcomes of merge prior to the decision. NHIFA implemented serious cost-containment measures as a consequence of the economic crisis. Despite of significant reduction in operational costs, the technical efficiency of the Clinical Center declined. The institution could not properly adapt to the loss of revenue caused by the PVL reduction after the merger. In difficult economic period the ceteris paribus assumption has to be supplemented with scenario analysis. 
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